Structural optimization and structure–activity relationship of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase

Article abstract of DOI:10.3390/molecules24152780

Human dihydroorotate dehydrogenase (hDHODH), one of the attractive targets for the development of immunosuppressive drugs, is also a potential target of anticancer drugs and anti-leukemic drugs. The development of promising hDHODH inhibitors is in high demand. Based on the unique binding mode of our previous reported 4-thiazolidinone derivatives, via molecular docking method, three new series 4-thiazolidinone derivatives were designed and synthesized as hDHODH inhibitors. The preliminary structure–activity relationship was investigated. Compound 9 of biphenyl series and compound 37 of amide series displayed IC₅₀ values of 1.32 μM and 1.45 μM, respectively. This research will provide valuable reference for the research of new structures of hDHODH inhibitors.

Full text of DOI:10.3390/molecules24152780

molecules
Article
Structural Optimization and Structure–Activity
Relationship of 4-Thiazolidinone Derivatives as
Novel Inhibitors of Human
Dihydroorotate Dehydrogenase
Fanxun Zeng 1,†, Lina Quan 2,†, Guantian Yang 1, Tiantian Qi 2, Letian Zhang 1, Shiliang Li 2,
Honglin Li 2, Lili Zhu 2,* and Xiaoyong Xu 1,
*
1
Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and
Technology, 130 Meilong Road, Shanghai 200237, China
Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering,
School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China
Correspondence: xyxu@ecust.edu.cn (X.X.); zhulfl@ecust.edu.cn (L.Z.); Tel.: +86-21-64252945 (X.X.);
+86-21-64253379 (L.Z.)
2
*
†
These authors contributed equally to this work.
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 23 June 2019; Accepted: 26 July 2019; Published: 31 July 2019
Abstract: Human dihydroorotate dehydrogenase (hDHODH), one of the attractive targets for
the development of immunosuppressive drugs, is also a potential target of anticancer drugs and
anti-leukemic drugs. The development of promising hDHODH inhibitors is in high demand. Based
on the unique binding mode of our previous reported 4-thiazolidinone derivatives, via molecular
docking method, three new series 4-thiazolidinone derivatives were designed and synthesized as
hDHODH inhibitors. The preliminary structure–activity relationship was investigated. Compound
9
of biphenyl series and compound 37 of amide series displayed IC50 values of 1.32 M and 1.45 M,
µ
µ
respectively. This research will provide valuable reference for the research of new structures of
hDHODH inhibitors.
Keywords: hDHODH inhibitors; structural optimization; structure–activity relationship;
4-thiazolidinones
1. Introduction
Pyrimidine, as a key precursor of RNA, DNA, glycoproteins, and phospholipids, plays a critical
role in cellular metabolism and cell growth [
1,
2]. Human dihydroorotate dehydrogenase (hDHODH) is
a mitochondrial enzyme that catalyzes the fourth step of de novo pyrimidine biosynthesis [3,4
]. Unlike
resting or fully differentiated cells which acquire pyrimidine mainly by the salvage pathways, rapidly
proliferating cells, such as activated T cells, depend heavily on de novo nucleotide synthesis to meet
their increased demand for nucleic acid precursors [5,6]. Thus, hDHODH would be an ideal drug target
for the treatment of variety of diseases such as tumor, immunological disorders and acute myeloid
leukemia [7–14].
Many hDHODH inhibitors have been developed and exhibited excellent therapeutic efficacy [15].
For example, leflunomide (1, Figure 1) was approved by FDA for the treatment of rheumatoid arthritis
in 1998 [16
teriflunomide via a base caused ring-opening reaction in vivo
cure multiple sclerosis later [20]. Brequinar (2), one of the strongest inhibitors of hDHODH, only showed
modest anticancer effects on a number of solid tumors in a phase II clinical trial [21 22]. Its effects
,17]. Then this compound was found to be a prodrug, forming its active metabolite
[
18 19]. Teriflunomide was developed to
,
,
Molecules 2019, 24, 2780; doi:10.3390/molecules24152780
www.mdpi.com/journal/molecules

Molecules 2019, 24, 2780
2 of 24
on autoimmune diseases and viral diseases were also extensively studied [23
–25]. Vidofludimus (3)
was proven to be a promising pharmaceutical agent in systemic lupus erythematosus, inflammatory
bowel disease, rheumatoid arthritis, and transplantation [ 26 28]. Vidofludimus also restored myeloid
7,
–
differentiation in leukemia cell lines at concentrations that are one log digit lower than those achieved
in experiments with brequinar [14]. The development of mL390 (4) that induced differentiation in acute
myeloid leukemia (AML) demonstrated that the inhibition of hDHODH could overcome differentiation
blockade in AML [29]. Recently compound 5 was reported to reduce tumor growth by increasing
p53 synthesis [30]. Compound 6 showed brequinar-like hDHODH potency in vitro and was superior
in terms of cytotoxicity and immunosuppression. In general, it is significant to develop promising
hDHODH inhibitors for the severe side effects of leflunomide/teriflunomide and the lack of newly
marketed hDHODH inhibitors.
Figure 1. Structures of representative inhibitors of hDHODH.
Recently we had described 4-thiazolidinone derivatives 7 and 8 as novel hDHODH inhibitors [31].
It was found that the binding mode of 4-thiazolidinone with hDHODH was different from the classic
inhibitors, that is, the thiazolidinone fragment locates at the outside of the bind pocket, cyano group
contacts ALA-59 by a water-mediated hydrogen bond, carbonyl and TYR-38 forms hydrogen bond
interaction, while the aromatic fragment contacts MET-43 by hydrophobic interaction (Figure 2A).
But, it was found that compound
site with its naphthalenyl group (Figure 2B,C) [31]. The binding mode of compound
8
only occupies the hydrophobic subsite of the ubiquinone-binding
suggested us
8
that the replacement of its naphthalenyl group with a suitable longer aryl group could orient the
new ligand towards the inner side of the binding site. An additional polar group, such as carboxyl
and acetyl, would generate hydrogen bond or salt bridge interactions with residue Arg-136 in the
hydrophilic subsite of the ubiquinone-binding site and may improve compounds’ binding affinity
against hDHODH. Therefore, further structural optimization of 4-thiazolidinone derivatives that
focused on the decoration of the aryl group to identify more potent hDHODH inhibitors was presented
in this study.

Molecules 2019, 24, 2780
3 of 24
Figure 2. Proposed binding modes of 4-thiazolidinone derivatives 7 (A) and 8 (B). The X-ray crystal
structure of hDHODH with PDB ID of 4LS1 was used in molecular docking. Figure 2C is an overlay of
compounds 7 and 8.
2. Results and Discussion
2.1. Molecular Design Strategies
In order to probe the inner subsite of the ubiquinone-binding site of hDHODH, biphenyl derivatives
were firstly designed and synthesized. The binding mode of
docking method reported previously [31 32]. It was shown that the introduction of 4-phenyl moiety
could enhance the hydrophobic interaction between the biphenyl compounds and the binding pocket
(Figures 3 and 4). In addition, by observing the binding modes of , we found that there is some space
9 was simulated using the same molecular
,
9
for substitution at the ortho-position of the phenyl group to enhance the hydrophobic interactions with
residues Met43, Leu46, Met111 and Pro364. Therefore, we tried to introduce a small fluorine atom into
the structure and synthesized compounds 10-18. However, compared with brequinar, a para-phenyl
might collide with the binding pocket, which would influence the binding affinity against the target
hDHODH (Figure 3). Therefore, phenoxy (phenoxymethyl) and phenyl amide groups were introduced
to improve the binding strength by adjusting the molecular configuration (Figure 5). After molecular
docking simulations, it was found that the introduction of an ether bond could cause an angle (about
109◦) to adjust the orientation of the phenyl group, which may be helpful to avoid the steric hindrance
between the ligand and the receptor (Figure 5). If the linker was replaced by a longer amide bond,
the whole molecule would also become longer, thus enabling the phenyl group to contact residues
in the inner binding site. When substituting a carboxyl group to the meta-position of the phenyl
group of the benzamide derivatives next, the carboxyl group would form hydrogen bond interactions
with residues Gln47 and Arg136, which are beneficial for strengthening the binding affinity of the
compounds (Figure 6). In addition, the amide bond could participate in a water-mediated hydrogen
bond network, which may be favorable for molecular binding. The results of docking simulations
suggested us that the design strategies may be feasible to improve the potency of the compounds. The
detailed modification strategies are described in Figures 4 and 7.
2.2. Chemistry
Key intermediates of compounds
18c were obtained by Suzuki cross-coupling reactions of compounds 9a
Etherification of compounds 19a 22a with 1-fluoro-4-nitrobenzene yielded compounds 19b
were reduced to afford compounds 19c 22c. Phenol was coupled with 1-fluoro-4-nitrobenzene to give
compound 23a. Etherification of (bromomethyl) benzene with 4-nitrophenol afforded compound 24a
9–
26 were synthesized according to Scheme 1. Compounds
18a with 9b 18b
22b, which
9c
–
–
–
.
–
–
–
,
which was reduced to give compound 24b. Compounds 25b and 26b were obtained by etherification
of compounds 25a, 26a with 4-nitrophenol, which were further reduced and hydrolyzed to give
compounds 25d and 26d.

Molecules 2019, 24, 2780
4 of 24
Figure 3. Binding mode of 4-thiazolidinone derivative
and brequinar is shown as cyan sticks.
9. Compound 9 is displayed as yellow sticks
NC
N
tBu
COOMe
S
COOMe
S
NC
R3
O
Optimization of the aryl group
R1
7. IC50 = 1.75 µM
NC
N
R2
O
COOMe
9-18
N
S
O
8. IC50 = 1.12 µM
Figure 4. Molecular design strategies of 4-thiazolidinones with biphenyl as hDHODH inhibitors.
Figure 5. Binding modes of 4-thiazolidinones with biphenyl ether structure (magenta sticks:
compound 10, orange sticks: compound 19).

Molecules 2019, 24, 2780
5 of 24
Figure 6. Proposed binding mode of benzamide-substituted 4-thiazolidinones as hDHODH inhibitors
(orange sticks: compound 41, gray sticks: compound 10).
R4
NC
N
COOMe
O
n
S
COOMe
NC
n = 0, 1
19-26
O
R3
R1
The second round optimization
S
N
O
R2
O
NC
N
COOMe
N
n
R5
H
biphenyl structure
n = 0, 1
27-46
S
O
Figure 7. Design and modification strategies of 4-thiazolidinones with biphenyl ether and amide as
hDHODH inhibitors.
Compound IM and key intermediates of compounds 40–46 were obtained according to
Scheme 2. 4-isothiocyanatobenzoic acid was prepared by reaction of 4-aminobenzoic acid with
1,1’-thiocarbonyldiimidazole (TCDI) in the presence of TEA. 4-Isothiocyanatobenzoic acid was treated
with methyl 2-cyanoacetate and potassium hydroxide in DMF to provide ketene-N, S-acetal salt, which
then reacted with 2-chloroacetyl chloride to give key intermediate IM.
Compounds 40c
,
41c were obtained by reduction of compounds 40b
, 41b, which were prepared
by amidation reactions of compounds 40a
,
41a with 4-nitrobenzoyl chloride. Compound 42b was
synthesized by hydrazinolysis of compound 42a, which was prepared by reaction of phthalide with
potassium phthalimide.
The important intermediate 43c was generated from starting material 3-cyanobenzoic acid
via protection, reduction, and amidation. Compound 44e was prepared from 1-(tert-butyl)-2-
methylbenzene via oxidation, nitration, reduction, amidation, and reduction.
Compound 45b was synthesized by amination of compound 45a, which was obtained by Friedel
-Crafts acylation of 2-bromonaphthalene. Intermediate 46b was obtained by removing Boc group of
compound 46a, which was obtained by amination of IM.

Molecules 2019, 24, 2780
6 of 24
Scheme 1. Synthesis of key intermediates of compounds 9–26.
The synthetic route to obtain target compounds
22e 23c, and 24d were obtained from corresponding aryl amines by two-step reactions. Key
intermediates 25e 26e 40d 41d 44f and compounds 26 40 41 44 were prepared by the same route
of 4-isothiocyanatobenzoic acid and IM, respectively. Compounds 27 39 42, and 45 were generated by
amination of intermediates 27a 39a 42b 45b with IM. Compound 43 was afforded by deprotection of
9–46 was shown in Scheme 3. Isothiocyanates
9e
–
,
,
,
,
,
9–
,
,
,
–
,
–
,
,
compound 43. The imidization of 46b with 2-formylbenzoic acid was introduced to give compound 46
.
2.3. Inhibitory Activities against hDHODH and SAR Study
In order to identify more potent compounds, biphenyl group was introduced for the size and
hydrophobicity of the aryl group which is essential for the activities. As shown in Table 1, the activity
of unsubstituted biphenyl derivative
9 was equal to that of compounds 7 and 8. Introducing a fluorine
atom into the biphenyl group (compounds 10 and 11) decreased the inhibitory activities. 20-Methyl
analog 12 had slightly less activity than 10. Introduction of a methoxy group into the 20-, 30-, or
40-positions of the biphenyl group (compounds 13
–
15) resulted in roughly 2-fold reduction in inhibitory
activity compared to compound 10, amongst the three compounds, the 30-methoxy derivative 14 was
slightly more potent than compounds 13 15. Introduction of electron-withdrawing groups (compounds
16 18) also failed to enhance the potency. Moreover, the results of the bioassay also showed that the
,
–
ortho-substituted fluorine atom (compounds 10 and 11) did not make a positive contribution to the
binding affinity, indicating that there may be steric clashes.

Molecules 2019, 24, 2780
7 of 24
Scheme 2. Synthesis of IM and key intermediates of compounds 40–46.
Since the biphenyl derivatives only showed moderate potency, biphenyl groups were replaced
further by flexible aryl ethers further (Table 2). To our disappointment, diphenyl ether derivatives
19–23 displayed markedly diminished activity. The 3-phenoxyphenyl analog 23 was also inactive.
Benzyl ether derivative 24 exhibited moderate activity with an IC50 value of 4.32
decreased when a carboxyl group (compounds 25 and 26) was introduced.
µM. The activity

Molecules 2019, 24, 2780
8 of 24
Scheme 3. Synthesis of compounds 9–46.
Table 1. Structures and activities for 4-thiazolidinone analogs 9–18.
a
Compd
7
R
% Inhibition at 10 µM
hDHODH IC50 (µM)
79.1
1.75
8
9
80.3
73.8
1.12
1.32
10
11
12
58.8
33.9
57.6
3.52
>10
6.04

Molecules 2019, 24, 2780
9 of 24
Table 1. Cont.
a
Compd
13
R
% Inhibition at 10 µM
hDHODH IC50 (µM)
54.7
63.3
55.4
50.2
6.64
5.42
6.86
8.39
14
15
16
17
18
50.7
53.1
4.35
9.29
Brequinar
0.0084
a
IC50 values were determined from three independent tests, and attempts to determine IC50 values were made if
the inhibition rate at 10 µM was greater than 50%.
Table 2. Structures and activities for 4-thiazolidinone analogs 19–46.
Compd
19
R
% Inhibition at 10 µM
hDHODH IC50 (µM)
52.0
9.43
20
21
44.7
29.7
>10
>10
22
23
24
18.1
34.4
55.4
>10
>10
4.32
25
26
27
29.9
36.2
41.7
>10
>10
>10

Molecules 2019, 24, 2780
10 of 24
Table 2. Cont.
Compd
28
R
% Inhibition at 10 µM
hDHODH IC50 (µM)
69.0
47.0
71.3
2.98
29
30
>10
3.01
31
53.6
8.56
32
33
34
52.7
42.0
38.1
7.50
>10
>10
35
36
37
24.5
55.4
75.6
>10
5.01
1.45
38
39
38.2
39.9
>10
>10
O
N
40
41
34.5
23.5
>10
>10
H
COOH
42
43
44
36.8
44.0
30.3
>10
>10
>10
45
46
42.2
34.8
>10
>10

Molecules 2019, 24, 2780
11 of 24
Then the moderate rigid and longer amide structure was introduced as a linker (compounds
27
–
46, Table 2). Phenyl derivative 28 showed a moderate activity, while the cyclohexyl analog 27 gave
a dramatically decreased activity. It indicated that rigid aromatic ring is better than flexible cyclohexyl
ring. Next we tried to introduce substituent groups into the phenyl group. A 4-tert-butyl substituent
(compound 37) was tolerated, while the introduction of smaller substituent groups such as CH3, F, Cl,
I, CF3, OCH3, CN etc. into the 2, 3 or 4-positions (compounds 29–36) was detrimental to the activity.
The naphthalen-2-yl derivative 38 and benzyl derivative 39 were inactive. Subsequently, COOH and
carbonyl groups were introduced to generate hydrogen bonds or salt bridge interactions with residue
Arg136 in the hydrophilic subsite of the ubiquinone-binding site. However, the inhibition rates of the
corresponding analogs 40–46 at 10 µM were still less than 50%. The bioassay results did not match
our modeling results. It indicated that neither ether nor amide is an appropriate linker to extend the
molecules to fit well in the pocket and eventually contact the inner residues Arg136 and Gln47.
Although the introduction of a biphenyl, diphenyl ether and amide structures into 4- thiazolidinone
did not obviously increase the rate of inhibition of hDHODH, the attempts can provide some ideas
for hDHODH inhibitor lead identification. We speculate that there may exist steric clashes caused
by inappropriate biphenyl, ether and amide group linkers. Thus, we will try some other linkers
like -C=N-N-, -C-C(=O)-, and -C-C(=O)-C- to replace the O of biphenyl ether or the CONH of the
amide series in our future work to further investigate the SAR and to obtain more potent DHODH
inhibitors. In addition, it was found that any changes to the structure connecting the N-terminus of
thiazolidone have a weak influence on the bioactivities, which means that thiazolidone is important to
increase the activity. In our future work, we will try to select other heterocycles and investigate the
stability of thiazolidones under the determination conditions to further establish the factors influencing
the bioactivity.
3. Materials and Methods
3.1. General Information
Unless otherwise indicated, all commercially available solvents and reagents were purchased
directly from commercial suppliers and used as received without further purification. Melting points
(m.p.) were recorded on Büchi B540 apparatus (Büchi Labortechnik AG, Flawil, Switzerland) and are
1
uncorrected. H-NMR, 19F-NMR and 13C-NMR spectra were recorded on an AM-400 (1H at 400 MHz,
13C at 100 MHz, 19F at 376 MHz) spectrometer (Bruker BioSpin AG, Fällanden, Switzerland) with
CDCl3 or DMSO-d6 as the solvent and TMS as the internal standard. Chemical shifts are reported in
δ
(parts per million) values. The following abbreviations were used to explain the multiplicities: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, coupling constant (Hz) and integration.
High-resolution electron mass spectra (ESI-TOF) were performed on a Micromass LC-TOF spectrometer
(Waters Co.,Ltd., Milford, MA, USA). High resolution mass spectra (HRMS) were recorded under
electron impact (70 eV) conditions using a MicroMass GCT CA 055 instrument (Waters Co.,Ltd.,
Milford, MA, USA). Analytical thin-layer chromatography (TLC) was carried out on precoated plates
(silica gel 60 F254) and spots were visualized with ultraviolet (UV) light.
3.2. Chemistry
3.2.1. Synthesis of Key Intermediates of Compounds 9–26.
General Procedure for the Synthesis of Intermediates 9c–18c
Substituted 4-iodoanilines 9b–18b (5 mmol), substituted phenylboronic acids 9a–18a (6 mmol), an
orange solution of Pd(dba)2 (2 mol%) and triphenylphosphine (6 mol%) were added in a tube. The tube
was evacuated and back-filled with argon. Potassium carbonate (20 mmol) solution (10 mL, 2 mol/L)
and ethanol (10 mL) were added using syringe, and the mixture was stirred and refluxed for 3–5 h.
After completion of the reaction, the reaction solution was extracted three times with ethyl acetate.

Molecules 2019, 24, 2780
12 of 24
The combined organic phases were dried over Na2SO4, and the solvent was removed under reduced
pressure. The residue was purified by column chromatography (Petroleum ether (PE)/Ethyl acetate
(EA)=10:1, V/V), to give 9c
accessed in Supplementary Materials).
–
18c in 65% 95% yield. (Spectrums for target compounds 7–46 could be
−
General Procedure for the Synthesis of Intermediates 19b–22b
K2CO3 (50 mmol) was carefully added to a solution of 19a
–
22a (12 mmol) and 1-fluoro-4-
nitrobenzene (10 mmol) in DMF (8 mL). The mixture was stirred at heating condition (120 ◦C for 19b
,
20b, and 22b, 60 ◦C for 21b) until the reaction was complete. The reaction mixture was diluted with
water (20 mL), extracted with EA after cooling to room temperature. The combined organic layer was
washed with 1 M NaOH, 1 M HCl and saturated salt water in order. Then the mixture was dried
(Na2SO4), concentrated under reduced pressure to give 19b–22b in yield of 70–90%, which was used
in the next step without further purification.
General Procedure for the Synthesis of Intermediates 19c–22c
Compounds 19b 22b (8 mmol) and Pd/C (10% w/w) were added to MeOH (40 mL). The resulted
mixture was reacted under H2 atmosphere at room temperature for 2 h. The mixture was filtered and
–
the filtrate was concentrated under reduced pressure to give 19c–22c in yield of 95–98%, which was
used in the next step without further purification.
Synthesis of Intermediate 23a
Phenol (12 mmol), 3-bromoaniline (10 mmol), K2CO3 (20 mmol), 1-butyl-1H-imidazole (5 mmol),
and CuCl (4.5 mmol) were added to o-xylene (10 mL) under Ar atmosphere, and the mixture was
heated to 140 ◦C for 20h. After cooling to room temperature, the mixture was filtered. The filtrate was
concentrated under reduced pressure and purified by column chromatography (PE/EA=4:1, V/V) to
give 23a in yield of 90%.
Synthesis of Intermediate 24a
K2CO3 (20 mmol) was added to a solution of (bromomethyl)benzene (12 mmol) and 4-nitrophenol
(10 mmol) in DMF (10 mL). The resulted mixture was allowed to react at 90 ◦C for 2 h. The mixture
was diluted with water (50 mL) after cooling to room temperature. The resulted mixture was filtered,
washed with water. The filter cake was further crystallized from EtOH to give target compound in
yield of 80%.
Synthesis of Intermediate 24b
Zinc powder (120 mmol) and AcOH (400 mmol) were added to a solution of 24a (8 mmol) in DCM
(45 mL) in ice bath. The mixture was stirred at room temperature until the reaction was completed. The
reaction mixture was filtered. The filtrate was washed with water, dried (Na2SO4) and concentrated
under reduced pressure. The residue was further purified by column chromatography (PE/EA=4:1,
1
V/V) to give 24b in yield of 80%. H-NMR (CDCl3): δ 7.39 – 7.31 (m, 4H) 7.27 (d, J = 6.4 Hz, 1H), 6.69
(d, J = 8.4 Hz, 2H), 6.55 (d, J = 8.4 Hz, 2H), 4.27 (s, 2H), 4.16 (s, 2H) ppm; 13C-NMR (CDCl3):
δ 147.79,
142.42, 139.61, 128.62, 127.60, 127.22, 116.21, 114.37, 49.36 ppm.
General Procedure for the Synthesis of Intermediates 25b and 26b
K2CO3 (15 mmol) was added to a solution of compounds 25a, 26b (10 mmol), and 4-nitrophenol
(11 mmol) in DMF (30 mL) under Ar atmosphere, and the mixture was heated to 120 ◦C for 4 h. The
mixture was diluted with water (50 mL) after cooling to room temperature. The resulted mixture was
filtered, washed with water. The filter cake was dried to give target compounds 25b and 26b.

Molecules 2019, 24, 2780
13 of 24
1
2-((4-Nitrophenoxy)methyl)benzonitrile (25b): H-NMR (CDCl3):
δ 8.26–8.21 (m, 2H), 7.75 (d, J = 7.6 Hz,
1H), 7.70–7.64 (m, 2H), 7.52–7.47 (m, 1H), 7.11–7.06 (m, 2H). 5.35 (s, 2H) ppm; 13C-NMR (CDCl3):
162.97, 142.20, 138.97, 133.27, 133.15, 129.05, 128.63, 126.04, 116.85, 114.91, 111.50, 68.16 ppm.
δ
General Procedure for Synthesis of Intermediates 25c and 26c
Reduced iron powder (100 mmol) and concentrated hydrochloric acid (0.5 mL) were carefully
added to a mixture of compounds 25b 26b, EtOH (60 mL) and water (6 mL). The reaction was reacted
,
under reflux condition until the reaction was completed. The reaction mixture was filtered and the
filter cake was washed with some EA. The filtrate was concentrated and used in the next step without
further purification.
3-((4-Aminophenoxy)methyl)benzonitrile (26c): 1H-NMR (CDCl3):
δ 7.68 (d, J = 7.6 Hz, 2H), 7.61 (t,
J = 7.6 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.8 Hz, 2H), 5.18 (s, 2H) ppm;
13C- NMR (CDCl3):
68.52 ppm.
δ 151.30, 141.22, 140.89, 133.01, 132.80, 128.45, 128.21, 117.15, 116.37, 116.35, 111.04,
General Procedure for Synthesis of Intermediates 25d and 26d
15% KOH (100 mL) was added to a mixture of compounds 25c, 26c and EtOH (25 mL) under Ar
atmosphere, and the mixture was reacted under reflux condition for 36 h. The reaction mixture was
washed with EA (30 mL), acidified with 1 N HCl, and extracted with EA. The combined organic layer was
washed with saturated NaCl, dried (Na2SO4), concentrated and purified by column chromatography
(DCM/MeOH=10:1, V/V) to give 25d, 26d in yield of about 40%.
1
2-((4-Aminophenoxy)methyl)benzoic acid (25d): H-NMR (DMSO-d6):
δ 10.62 (s, 3H), 7.94 (d, J = 7.6 Hz,
1H), 7.66–7.56 (m, 2H), 7.48–7.43 (m, 1H), 7.33 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 8.8 Hz, 2H), 5.47 (s,
2H) ppm; 13C-NMR (DMSO-d6):
δ 168.05, 157.67, 137.86, 132.09, 130.47, 129.53, 127.96, 127.77, 124.64,
124.38, 115.60, 67.91 ppm.
Synthesis of Intermediate IM
4-Aminobenzoic acid (5 mmol) was slowly added to a solution of TCDI (6 mmol) and TEA
(5.5 mmol) in DCM (7.5 mL) at 0 ◦C. The mixture was stirred for 2h at 0 ◦C and then added dropwise to
4M aqueous HCl (9 mL). The precipitation was filtered and washed with 1M aqueous HCl (1 mL 2). The
×
resulting sold was dried to afford 4-isothiocyanatobenzoic acid in yield of 90%. Methyl 2-cyanoacetate
(2 mmol) followed by a solution of 4-isothiocyanatobenzoic acid (2 mmol) in anhydrous DMF (2 mL)
were added to a cold suspension of powdered KOH (4 mmol) in dry DMF (2 mL). The mixture was
stirred at room temperature for 0.5 h, then cooled again to 0 ◦C, treated with a solution of 2-chloroacetyl
chloride (3 mmol) in anhydrous DMF (2 mL) and stirred at room temperature overnight. The mixture
was poured into ice-cold water, and the resulting precipitate was filtered off, dried, and crystallized
from DCM-EtOH to give intermediate IM in yield of 68%. Mp 290.1-290.7 ◦C. 1H-NMR (DMSO-d6):
δ
13.28 (s, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 4.08 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR
(DMSO-d6):
δ 173.30, 172.30, 166.57, 165.31, 138.53, 132.45, 130.22, 129.71, 112.32, 75.76, 52.38, 32.27 ppm.
HRMS (EI) calc. for C12H8N2O3S+ 318.0310; found 318.0312.
General Procedure for the Synthesis of Intermediates 40b and 41b
TEA (15 mmol) followed by 4-nitrobenzoyl chloride (10 mmol) was dropwise added to a solution
of compound 40a, 41a in THF (40 mL) in ice bath. The mixture was allowed to stir at room temperature
overnight. Then the mixture was diluted with water (50 mL), acidified with 1 M HCl, filtered. The
filter cake was washed with water, crystallized from DCM-MeOH to give intermediate 40b, 41b.
3-(4-Nitrobenzamido)benzoic acid (41b): 1H-NMR (DMSO-d6):
J = 8.8 Hz, 2H), 8.23 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz
δ 10.80 (s, 1H), 8.43 (s, 1H), 8.23 (d,
,

Molecules 2019, 24, 2780
14 of 24
1H) ppm; 13C-NMR (DMSO-d6):
δ
167.08, 164.04, 149.19, 140.22, 138.91, 131.25, 129.25, 128.98, 124.92,
124.52, 123.53, 121.21 ppm.
General Procedure for the Synthesis of Intermediates 40c and 41c
Compounds 40c and 41c were prepared from 40b and 41b according the same procedure described
for 19c–22c.
Synthesis of Intermediate 42a
Phthalide (10 mmol) and potassium phthalimide (11 mmol) was added to DMF (7 mL). The
mixture was stirred under reflux condition until the reaction was completed. 35% AcOH (11 mL) was
added after cooling to room temperature. The resulted mixture was filtered after stirring for 0.5 h.
The filter cake was washed with water and EtOH in order, crystallized from DCM-MeOH to give
intermediate 42a in yield of 56%.
Synthesis of Intermediate 42b
Compound 42a (5 mmol) was dissolved in DMF (10 mL) and EtOH (20 mL). The mixture was
heated to 75 ◦C, added 80% hydrazine hydrate (0.6 mL) and stirred at this temperature overnight. The
mixture was filtered after cooling to room temperature. The filtrate was concentrated to give 42b in
yield of 80%.
Synthesis of Intermediate 43a
Concentrated H2SO4 (30 mmol) was added to a mixture of magnesium sulfate (120 mmol) and
DCM (120 mL). Then 3-cyanobenzoic acid (30 mmol) and tert-butanol were added after stirring for
15 min. The mixture was stirred at room temperature for 24 h and filtered. The filtrate was neutralized
with saturated NaHCO3, diluted with water, and extracted with DCM. The combined organic layer
was washed with saturated NaCl, concentrated and purified by column chromatography (PE/EA=3:1,
1
V/V) to give 43a in yield of 58%. H-NMR (DMSO-d6):
δ 8.25 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.10 (d,
J = 8.0 Hz, 1H), 7.72 (t, J = 8.0 Hz, 1H), 1.56 (s, 9H) ppm. 13C-NMR (DMSO-d6):
δ 163.21, 136.23, 133.41,
132.47, 132.40, 130.04, 117.97, 111.91, 81.87, 27.62 ppm.
Synthesis of Intermediate 43b
A mixture of HCOOH and TEA (25 mL, V:V=5:1) followed by Pd/C (1.1 g) was slowly added to a
solution of compound 43a in THF (25 mL) under Ar atmosphere. The mixture was stirred at 40 ◦C for
4 h and filtered. The filtrate was neutralized with saturated NaHCO3 and concentrated to remove THF.
The residue was extracted with EA. The combined organic layer was washed with saturated NaCl,
dried (Na2SO4), and concentrated to give compound 43b. GC-MS m/z 207 [M]+.
Synthesis of Intermediate 43c
Compound 43b (2 mmol), IM (2 mmol), and 4-dimethylaminopyridine (DMAP, 20 mg) was
added to DCM (20 mL). Then 1-ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride (EDCI,
4 mmol) was added. The mixture was stirred at room temperature until the reaction was completed,
and concentrated. The residue was purified by column chromatography (PE/EA=4:3, V/V) to give 43c
1
in yield of 68%. H-NMR (DMSO-d6):
δ 9.28 (t, J = 6.0 Hz, 1H), 8.02 (d, J = 8.8 Hz, 2H), 7.89 (s, 1H),
7.79 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 4.55 (d,
J = 6.0 Hz, 2H), 4.09 (s, 2H), 3.71 (s, 3H), 1.54 (s, 9H) ppm.
Synthesis of Intermediate 44a
KMnO4 (60 mmol) was added to a solution of 1-(tert-butyl)-2-methylbenzene in tert-butanol
(60 mL) and water (60 mL). The mixture was stirred under reflux condition until the reaction was

Molecules 2019, 24, 2780
15 of 24
completed and filtered. The filtrate was concentrated to remove tert-butanol, acidified with concentrated
HCl, and filtered. The filter cake was dried to give 44a, which was directly used in the next step.
Synthesis of Intermediate 44b
Compound 44b was dissolved in concentrated H2SO4 (25 mL) and cooled to 0 ◦C. Then a solution
of KNO3 (20 mmol) in concentrated H2SO4 (25 mL) was dropwise added to the mixture. The mixture
was reacted at 0 ◦C until the reaction was completed, and dropwise added to ice water. The resulted
mixture was filtered and washed with water. The filter cake was dried and crystallized from EtOH
1
to give intermediate 44b in yield of 40% over two steps. H-NMR (DMSO-d6):
δ 13.75 (s, 1H), 8.21
(dd, J = 8.8, 2.8 Hz, 1H), 8.10 (d, J = 2.8 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 1.43 (s, 9H) ppm; 13C-NMR
(DMSO-d6): δ 170.88, 153.99, 144.99, 135.54, 128.88, 123.82, 122.76, 36.35, 30.62 ppm.
Synthesis of Intermediate 44c
Compound 44b (10 mmol) was added to a mixture of EtOH (60 mL) and water (15 mL). Then
reduced iron powder (100 mmol) and concentrated HCl (10 drops) were added. The mixture was
stirred under reflux condition until the reaction was completed, filtered. The filter cake was washed
with EA. The filtrate was concentrated and directly used in the next step.
Synthesis of Intermediate 44d
4-Nitrobenzoyl chloride (6 mmol) was slowly added to a mixture of compound 44c, DCM (30 mL),
and TEA (10 mmol). The obtained mixture was stirred at room temperature until the reaction was
completed. The mixture was acidified with 1 M HCl and filtered. The filter cake was washed with
water, dried and crystallized from DCM/MeOH to give intermediate 44d in yield of 40% over two steps.
1H-NMR (DMSO-d6):
δ
13.15 (s, 1H), 10.61 (s, 1H), 8.42–8.35 (m, 2H), 8.23–8.17 (m, 2H), 7.81–7.76 (m,
172.65, 163.77, 149.18, 141.93,
2H), 7.49 (d, J = 9.2 Hz, 1H), 1.39 (s, 9H) ppm; 13C-NMR (DMSO-d6):
δ
140.26, 136.09, 134.46, 129.16, 127.25, 123.54, 120.89, 119.73, 35.23, 31.10 ppm.
Synthesis of Intermediate 44e
Compound 44e was prepared from 44d in the same manner as described for 44c.
1H-NMR
(DMSO-d6):
δ 13.00 (s, 1H), 9.79 (s, 1H), 7.78–7.66 (m, 4H), 7.45–7.34 (m, 1H), 6.60 (d, J = 8.8 Hz, 2H),
5.76 (s, 2H), 1.37 (s, 9H) ppm; 13C-NMR (DMSO-d6):
δ 165.20, 152.17, 140.36, 137.12, 129.31, 126.83,
120.79, 120.29, 119.28, 112.50, 79.15, 35.09, 31.18 ppm.
Synthesis of Intermediate 45a
2-Bromonaphthalene (50 mmol) was dissolved in dry DCM under Ar atmosphere and cooled to
-10 ◦C. Then the mixture was added AlCl3 (150 mmol) and stirred until it turns green. Then acetyl
chloride was added after cooling to -78 ◦C and stirred at this temperature for 3 h. The mixture was
quenched with 1 M HCl, diluted with water, and extracted with DCM. The combined organic phases
were washed with 1 M HCl and saturated NaCl in order, dried over Na2SO4, and the solvent was
removed under reduced pressure. The residue was purified by column chromatography (PE/EA=4:1,
1
V/V) to give 45d in yield of 89%. H-NMR (CDCl3):
δ 9.03 (d, J = 2.0 Hz, 1H), 7.99 (dd, J = 7.2, 1.0 Hz,
1H), 7.96 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.62 (dd, J = 8.8, 2.0 Hz, 1H), 7.52 (dd, J = 8.4,
7.2 Hz, 1H), 2.74 (s, 3H) ppm; 13C-NMR (CDCl3):
128.57, 124.76, 123.01, 29.76 ppm.
δ 201.06, 134.13, 133.08, 132.42, 131.13, 130.04, 129.84,
Synthesis of Intermediates 45b
Compound 45a (20 mmol), ammonia (100 mmol), CuI (4 mmol), L-proline (8 mmol), and K2CO3
(60 mmol) was suspended in DMSO (40 mL) under Ar atmosphere. The mixture was stirred at 85 ◦C
for 24 h, and filtered after cooling to room temperature. The filter cake was washed with EA. The

Molecules 2019, 24, 2780
16 of 24
filtrate was diluted with water and extracted with EA. The combined organic phases were washed
with saturated NaCl, dried over Na2SO4, and the solvent was removed under reduced pressure. The
residue was purified by column chromatography (PE/EA=3:1, V/V) to give 45b in yield of 52%.
Synthesis of Intermediates 46a
DMAP (0.5 mmol) and tert-butyl carbazate (6 mmol) were added to a mixture of compound IM
and DCM (25 mL). Then the mixture was added EDCI (10 mmol) and stirred at room temperature until
the reaction was completed. The solvent was removed under reduced pressure and the residue was
1
purified by column chromatography (DCM/acetone=10:1, V/V) to give 46a in yield of 72%. H- NMR
(CDCl3):
δ
8.79 (s, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 6.86 (s, 1H), 3.91 (s, 2H), 3.81 (s,
172.20, 170.07, 165.67, 165.62, 155.69, 137.12, 129.25, 129.15,
3H), 1.50 (s, 9H) ppm; 13C-NMR (CDCl3):
δ
111.85, 81.99, 78.88, 52.90, 31.79, 28.34, 28.18 ppm.
Synthesis of Intermediate 46b
CF3COOH was added to a solution of compound 46a in DCM (45 mL). The mixture was stirred at
room temperature overnight and concentrated to give 46b, which was directly used in the next step.
Synthesis of Aryl Isothiocyanates 9e–22e, 23c, 24d
A mixture of 1,4-diazabicyclo(2.2.2) octane (DABCO, 15 mmol), aromatic amines 9c–22c, 23a, 24b
(5 mmol), and carbon disulfide (25 mL) in acetone (5 mL) was stirred overnight at room temperature.
The precipitated solid was filtered. To a mixture of the solid and chloroform (20 mL) at 0 ◦C, was added
dropwise a solution of triphosgene (2 mmol) in chloroform (10 mL) over 30 min. The reaction mixture
was allowed to warm to room temperature and stirred overnight. After the resulting mixture was
filtered, the filtrate was concentrated under reduced pressure and purified by column chromatography
(100% PE) to give 9c–22c, 23a, 24b in 70%–95% yield as white solids or colorless oils.
Synthesis of Aryl Isothiocyanates 25e, 26e, 40d, 41d, 44f
Isothiocyanates 25e, 26e, 40d, 41d and 44f were prepared from 25d, 26d, 40c, 41c, 44e in the same
manner as described for 4-isothiocyanatobenzoic acid.
3.2.2. Synthesis of Compounds 9–26, 40, 41, 44
Compounds
9–
26,
40
,
41 and 44 were prepared from 9e
–
22e
,
23c
,
24d
,
25e
, 26e, 40d, 41d, 44f in
the same manner as described for compound IM.
Methyl (Z)-2-(3-([1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (
9
). Mp 235.1–235.5 ◦C.
1H-NMR (DMSO-d6):
δ 7.82 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 8.0 Hz, 4H), 7.43 (t,
J = 7.2 Hz, 1H), 4.10 (s, 2H), 3.72 (s, 3H) ppm. HRMS (ES+) calcd for C19H14N2O3S (M + H)+,351.0803;
found, 351.0802.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (10).
Mp
◦
1
180.0–180.1 C. H-NMR (DMSO-d6):
δ
7.83–7.79 (m, 3H), 7.72 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H),
7.66 (t, J = 7.6 Hz, 1H), 7.56–7.43 (m, 3H), 4.24 (ABq, Jgem = 18.8 Hz, 2H), 3.74 (s, 3H) ppm. 19F-NMR
(DMSO-d6): δ −121.94 (t, J = 9.4 Hz) ppm. HRMS (ES+) calcd for C19H13FN2O3S (M + H)+,369.0703;
found, 369.0709.
Methyl (Z)-2-cyano-2-(3-(3,5-difluoro-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (11). Mp
◦
1
185.6–186.0 C. H-NMR (DMSO-d6):
δ 7.82 (dd, J1 = 16.8 Hz, J2 = 6.8 Hz, 4H), 7.55–7.47 (m,
3H), 4.40 (s, 2H), 3.76 (s, 3H) ppm. 19F-NMR (DMSO-d6): δ −118.44 (d, J = 11.1 Hz) ppm. HRMS (ES+)
calcd for C19H12F2N2O3S (M + H)+,387.0615; found, 387.0621.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-2’-methyl-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (12). Mp
198.6–198.9 ◦C. 1H-NMR (400 MHz, DMSO-d6):
δ 7.63 (t, J = 8.0 Hz, 1H), 7.44 (d, J = 10.8 Hz, 1H),

Molecules 2019, 24, 2780
17 of 24
7.33–7.26 (m, 5H), 4.25 (ABq, Jgem = 18.8 Hz, 2H), 3.75 (s, 3H), 2.26 (s, 3H) ppm. 19F NMR (376 MHz,
DMSO-d6): δ −122.72 (t, J = 9.4 Hz) ppm. HRMS (ES+) calcd for C20H15FN2O3S (M + H)+, 383.0866;
found, 383.0868.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-2’-methoxy-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (13).
Mp 220.1–220.5 ◦C. 1H-NMR (DMSO-d6):
δ
7.59 (t, J = 8.0 Hz, 2H), 7.50 (dd, J1 = 8.4 Hz, J2 = 1.6Hz, 1H),
7.43 (td, J1 = 8.0Hz, J2 = 1.6 Hz, 1H), 7.37 (dd, J1 = 7.2 Hz, J2 = 1.6Hz, 1H), 7.18 (d, J = 8.0 Hz,1H), 7.08
(t, J = 7.4 Hz, 1H), 4.24 (ABq, Jgem = 18.8 Hz, 2H), 3.82 (s, 3H), 3.75 (s, 3H) ppm. 19F-NMR (DMSO-d6):
123.08 (dd, J1 = 12.8 Hz, J2 = 8.5 Hz) ppm. HRMS (ES+) calcd for C20H15FN2O4S (M + H)+, 399.0815;
found, 399.0814.
δ
−
Methyl (Z)-2-cyano-2-(3-(3-fluoro-3’-methoxy-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (14).
Mp 193.1–193.6 ◦C. 1H-NMR (DMSO-d6):
7.84 (dd, J1 = 11.6 Hz, J2 = 1.6Hz, 1H), 7.73 (dd, J1 = 8.4 Hz
δ
,
J2 = 1.6Hz, 1H), 7.65 (t, J = 8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.35 (t, J = 8.0 Hz,2H), 7.03 (dd,
J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 4.24 (ABq, Jgem = 18.8 Hz, 2H), 3.86 (s, 3H), 3.75 (s, 3H) ppm. 19F-NMR
(DMSO-d6): δ −121.97 (dd, J1 = 12.8 Hz, J2 = 9.4 Hz) ppm. HRMS (ES+) calcd for C20H15FN2O4S (M +
H)+, 399.0815; found, 399.0821.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-4’-methoxy-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (15).
Mp 177.1–177.3 ◦C. 1H-NMR (DMSO-d6):
δ 7.77–7.72 (m, 3H), 7.65 (d, J = 8.8 Hz, 1H), 7.59 (t, J = 8.0 Hz,
1H), 7.07 (d, J = 8.8 Hz, 2H), 4.22 (ABq, Jgem = 18.6 Hz, 2H), 3.83 (s, 3H), 3.74 (s, 3H) ppm. 19F-NMR
(DMSO-d6): δ −122.12 (dd, J1 = 13.2 Hz, J2 = 8.9 Hz) ppm. HRMS (ES+) calcd for C20H15FN2O4S (M +
H)+, 399.0815; found, 399.0816.
Methyl (Z)-2-cyano-2-(3-(3’-cyano-3-fluoro-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene)acetate (16). Mp
191.2–191.3 ◦C. 1H-NMR (DMSO-d6):
δ 8.33 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.95 (dd, J1 = 11.2 Hz,
J2 = 7.6 Hz, 2H), 7.83 (d, J = 8.4 Hz, 1H), 7.72 (q, J = 7.6 Hz, 2H), 4.24 (ABq, Jgem = 18.8 Hz, 2H), 3.75 (s,
3H) ppm. 19F-NMR (DMSO-d6): δ −121.44 (td, J1 = 8.9 Hz, J2 = 3.4 Hz) ppm. HRMS (ES+) calcd for
C20H12FN3O3S (M + H)+, 394.0662; found, 394.0668.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-3’-nitro-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene) acetate (17). Mp
179.2–179.9 ◦C. 1H-NMR (DMSO-d6):
δ 8.57–8.56 (m, 1H), 8.32–8.26 (m, 2H), 8.02 (dd, J1 = 11.2 Hz,
J2 = 2.0 Hz, 1H), 7.88–7.80 (m, 2H), 7.74 (t, J = 8.0 Hz, 1H), 4.24 (ABq, Jgem = 18.4 Hz, 2H), 3.75 (s,
3H). 19F-NMR (DMSO-d6): δ −121.31 (t, J = 10.6 Hz). HRMS (ES+) calcd for C19H12FN3O5S (M + H)+,
413.3851; found, 413.3853.
Methyl (Z)-2-cyano-2-(3-(3-fluoro-3’-(trifluoromethyl)-[1,1’-biphenyl]-4-yl)-4-oxothiazolidin-2-ylidene) -acetate
◦
1
(
18). Mp 182.4–183.1 C. H-NMR (DMSO-d6): δ 8.12 (s, 1H), 7.98 (d, J = 11.2 Hz, 1H), 7.83 (dd,
J1 = 8.4 Hz, J2 = 3.2Hz, 2H), 7.78–7.70 (m, 2H), 4.18 (ABq, Jgem = 18.8 Hz, 2H), 3.75 (s, 3H) ppm.
19F-NMR (DMSO-d6): δ −61.03 (s), -121.55(dd, J1 = 12.3 Hz, J2 = 8.9 Hz) ppm. HRMS (ES+) calcd for
C20H12F4N2O3S (M + H)+, 437.0583; found, 437.0591.
Methyl (Z)-2-cyano-2-(4-oxo-3-(4-phenoxyphenyl)thiazolidin-2-ylidene)acetate (19). White solid, Yield: 72%.
Mp 167.6–168.3 ◦C; 1H-NMR (DMSO-d6):
δ
7.46–7.42 (m, 2H), 7.39 (t, J = 8.0 Hz, 2H), 7.18–7.12 (m, 3H),
7.07 (d, J = 8.0 Hz, 2H), 4.07 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ
173.40, 173.13, 165.44,
157.97, 156.72, 131.34, 130.08, 130.01, 123.56, 119.73, 118.35, 112.40, 75.73, 52.35, 32.17 ppm. HRMS (EI)
calc. for C19H14N2O4S+ 366.0674; found 366.0675.
Methyl (Z)-2-cyano-2-(3-(4-(2-methoxyphenoxy)phenyl)-4-oxothiazolidin-2-ylidene)acetate (20). White solid,
Yield: 74%. Mp 181.2–182.1 ◦C; 1H-NMR (DMSO-d6):
δ
7.34 (d, J = 8.8 Hz, 2H), 7.25–7.16 (m, 2H),
7.05 (dd, J = 8.0, 1.2 Hz, 1H), 6.99–6.93 (m, 3H), 4.05 (s, 2H), 3.75 (s, 3H), 3.71 (s, 3H) ppm. 13C-NMR
(DMSO-d6):
δ 173.48, 173.02, 165.48, 159.03, 151.09, 143.57, 130.83, 128.87, 125.66, 121.13, 121.04, 117.08,
113.45, 112.28, 75.80, 55.61, 52.32, 32.08 ppm. HRMS (EI) calc. for C20H16N2O5S+ 396.0780; found
396.0779.

Molecules 2019, 24, 2780
18 of 24
Methyl (Z)-2-cyano-2-(4-oxo-3-(4-(2-(trifluoromethyl)phenoxy)phenyl)thiazolidin-2-ylidene)acetate (21).
◦
1
White solid, Yield: 72%.Mp 159.7–161.3 C; H-NMR (DMSO-d6):
δ 7.61 (t, J = 8.2 Hz, 1H), 7.52
(d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 6.4 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H), 4.08 (s, 2H),
3.72 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.35, 173.07, 165.42, 157.74, 156.76, 131.78, 131.23, 131.16,
130.77 (q, 2JCF = 31.9 Hz), 123.65 (q, 1JCF = 270.9 Hz), 121.75, 120.84, 119.73 (q, 3JCF = 3.8 Hz), 114.15 (q,
3JCF = 3.8 Hz), 112.42, 75.79, 52.35, 32.20 ppm. 19F-NMR (DMSO-d6): δ −61.13 (s, 3F) ppm. HRMS (EI)
calc. for C20H13F3N2O4S+ 434.0548; found 434.0550.
Methyl (Z)-2-(3-(4-(4-(tert-butyl)phenoxy)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (22). White
solid, Yield: 74%. Mp 212.9–213.9 ◦C; 1H-NMR (DMSO-d6):
δ
7.41 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz
,
2H), 7.11 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 4.07 (s, 2H), 3.71 (s, 3H), 1.28 (s, 9H) ppm. 13C-NMR
(DMSO-d6):
δ 173.40, 173.11, 165.45, 158.35, 154.28, 145.96, 131.24, 129.81, 126.67, 119.40, 118.05, 112.35,
75.76, 52.34, 34.03, 32.15, 31.21 ppm. HRMS (EI) calc. for C23H22N2O4S+ 422.1300; found 422.1299.
Methyl (Z)-2-cyano-2-(4-oxo-3-(3-phenoxyphenyl)thiazolidin-2-ylidene)acetate (23). White solid, Yield: 76%.
Mp 183.4–184.3 ◦C; 1H-NMR (DMSO-d6):
δ
7.52 (t, J = 8.0 Hz, 1H), 7.39 (t, J = 8.0 Hz, 2H), 7.25–7.20
(m, 2H), 7.17–7.12 (m, 2H), 7.10 (d, J = 8.0 Hz, 2H), 4.01 (ABq, Jgem = 18.4 Hz, 2H), 3.71 (s, 3H) ppm.
13C-NMR (DMSO-d6):
δ 173.25, 172.68, 165.40, 157.06, 156.64, 136.07, 130.69, 130.04, 124.60, 123.63,
121.35, 119.87, 118.48, 112.51, 75.57, 52.36, 32.19 ppm. HRMS (EI) calc. for C19H14N2O4S+ 366.0674;
found 366.0675.
Methyl (Z)-2-(3-(4-(benzyloxy)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (24). White solid, Yield:
◦
1
75%. Mp 202.0–202.8 C; H-NMR (DMSO-d6):
δ 7.47 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.2 Hz, 2H),
7.37–7.34 (m, 1H), 7.31 (dt, J = 8.8, 2.6 Hz, 2H), 7.11 (dt, J = 8.8, 2.6 Hz, 2H), 5.15 (s, 2H), 4.05 (s, 2H), 3.70
(s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.51, 173.12, 165.51, 159.73, 136.62, 130.54, 128.44, 127.91, 127.74,
127.48, 115.18, 112.24, 75.74, 69.49, 52.31, 32.00 ppm. HRMS (EI) calc. for C20H16N2O4S+ 380.0831;
found 380.0834.
(Z)-2-((4-(2-(1-Cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)phenoxy)methyl)benzoic acid (25).
White solid, Yield: 67%. Mp 210.6–211.5 ◦C; 1H-NMR (DMSO-d6):
δ
13.13 (s, 1H), 7.95 (d, J = 7.6 Hz,
1H), 7.65 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.07
(d, J = 8.8 Hz, 2H), 5.52 (s, 2H), 4.05 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.50, 173.12,
δ
168.05, 165.50, 159.68, 137.94, 132.17, 130.62, 130.50, 129.27, 127.80, 127.69, 127.57, 115.19, 112.22, 75.78,
67.88, 52.30, 32.02 ppm. HRMS (EI) calc. for C21H16N2O6S+ 424.0729; found 424.0728.
(Z)-3-((4-(2-(1-Cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)phenoxy)methyl)benzoic acid (26).
White solid, Yield: 68%. Mp 233.2–234.1 ◦C; 1H-NMR (DMSO-d6):
δ
13.02 (s, 1H), 8.06 (s, 1H), 7.92
(d, J = 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 7.13 (d,
J = 8.8 Hz, 2H), 5.24 (s, 2H), 4.05 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.48, 173.07,
δ
167.08, 165.50, 159.58, 137.24, 131.97, 130.99, 130.58, 128.78, 128.38, 127.63, 115.23, 112.23, 75.78, 68.94,
52.30, 32.00 ppm. HRMS (EI) calc. for C21H16N2O6S+ 424.0729; found 424.0730.
(Z)-2-(4-(2-(1-Cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)benzamido)benzoic acid (40). White
◦
1
solid, Yield: 70%. Mp 261.8–262.5 C; H-NMR (DMSO-d6):
J = 8.0 Hz, 1H), 8.14–8.06 (m, 3H), 7.74–7.63 (m, 3H), 7.24 (t, J = 7.4 Hz, 1H), 4.11 (s, 2H), 3.73 (s,
3H) ppm. 13C-NMR (DMSO-d6):
173.33, 172.24, 169.94, 165.31, 162.25, 140.80, 137.96, 136.10, 134.28,
δ 13.81 (s, 1H), 12.25 (s, 1H), 8.71 (d,
δ
131.26, 130.10, 128.01, 123.20, 120.06, 116.84, 112.36, 75.90, 52.37, 32.25, 30.73 ppm. HRMS (ESI) calc. for
C21H15N3O6SNa+ (M + Na)+, 460.0579; found 460.0578. HRMS (EI) calc. for C21H16N2O6S+ 424.0729;
found 424.0728.
(Z)-3-(4-(2-(1-Cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)benzamido)benzoic acid (41). White
solid, Yield: 68%. Mp 205.7–206.6 ◦C; 1H-NMR (DMSO-d6):
δ
12.98 (s, 1H), 10.57 (s, 1H), 8.45 (s, 1H),
8.13 (d, J = 7.6 Hz, 2H), 8.07 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 7.6 Hz, 2H), 7.50 (t,
J = 7.8 Hz, 1H), 4.10 (s, 2H), 3.72 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.33, 172.24, 169.94, 165.31,
δ

Molecules 2019, 24, 2780
19 of 24
162.25, 140.80, 137.96, 136.10, 134.28, 131.26, 130.10, 128.01, 123.20, 120.06, 116.84, 112.36, 75.90, 52.37,
32.25, 30.73 ppm. HRMS (ESI) calc. for C21H15N3O6SNa+ (M + Na)+, 460.0579; found 460.0580.
(Z)-2-(tert-butyl)-5-(4-(2-(1-cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)benzamido)benzoic acid
(
44). White solid, Yield: 69%. Mp 328.1–328.9 ◦C; 1H-NMR (DMSO-d6):
δ
13.13 (s, 1H), 10.44 (s, 1H),
8.10 (d, J = 8.8 Hz, 2H), 7.80 (dd, J = 8.4, 2.4 Hz, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.48
(d, J = 8.4 Hz, 1H), 4.10 (s, 2H), 3.72 (s, 3H), 1.39 (s, 9H) ppm. 13C-NMR (DMSO-d6):
173.39, 172.71,
δ
172.32, 165.35, 164.39, 141.59, 137.55, 136.35, 136.04, 134.42, 129.47, 128.66, 127.19, 120.88, 119.69, 112.38,
75.79, 52.40, 35.21, 32.23, 31.12 ppm. HRMS (EI) calc. for C25H23N3O6S+ 493.1308; found 493.1300.
3.2.3. Synthesis of Compounds 27–39, 45
General procedure for the synthesis of compounds 27–39, 45
Corresponding aromatic amines (1.2 mmol) and DMAP (0.1 mmol) were added to a mixture of
compound IM (1 mmol) and DCM (5 mL). Then the mixture was added EDCI (2 mmol) and stirred
at room temperature until the reaction was completed. The solvent was removed under reduced
pressure and the residue was purified by column chromatography (DCM/acetone=10:1, V/V) to give
compounds 27–39, 45.
Methyl (Z)-2-cyano-2-(3-(4-(cyclohexylcarbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate (27). White solid,
Yield: 78%. Mp 224.3–225.1 ◦C; 1H-NMR (DMSO-d6):
δ
7.33 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz,
2H), 4.06 (s, 2H), 3.69 (s, 3H), 2.57 (t, J = 9.6 Hz, 1H), 1.80 (d, J = 9.6 Hz, 4H), 1.71 (d, J = 12.4 Hz, 1H),
1.48–1.31 (m, 4H), 1.30–1.18 (m, 1H) ppm. 13C-NMR (DMSO-d6):
173.46, 172.71, 165.50, 149.98, 132.44,
δ
128.97, 127.46, 111.95, 75.90, 54.87, 52.30, 43.51, 33.80, 32.06, 26.22, 25.52 ppm. HRMS (EI) calc. for
C20H21N3O4S+ 399.1253; found 399.1251.
Methyl (Z)-2-cyano-2-(4-oxo-3-(4-(phenylcarbamoyl)phenyl)thiazolidin-2-ylidene)acetate (28). White solid,
Yield: 48%. Mp 194.9–195.6 ◦C; 1H-NMR (DMSO-d6):
δ
10.40 (s, 1H), 8.11 (d, J = 8.4 Hz, 2H), 7.80 (d,
J = 8.0 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.37 (t, J = 7.8 Hz, 2H), 7.13 (t, J = 7.2 Hz, 1H), 4.10 (s, 2H), 3.72
(s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.41, 172.35, 165.37, 164.44, 138.93, 137.47, 136.33, 129.45, 128.67,
128.62, 123.87, 120.49, 112.39, 75.79, 52.41, 32.24 ppm. HRMS (EI) calc. for C20H15N3O4S+ 393.0783;
found 393.0782.
Methyl (Z)-2-cyano-2-(4-oxo-3-(4-(o-tolylcarbamoyl)phenyl)thiazolidin-2-ylidene)acetate (29). White solid,
Yield: 50%. Mp 274.1–275.0 ◦C; 1H-NMR (DMSO-d6):
δ
10.05 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.59 (d,
J = 8.4 Hz, 2H), 7.36 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 7.2 Hz, 1H), 7.24 (t, J = 6.8 Hz, 1H), 7.19 (t, J = 7.4 Hz
1H), 4.10 (s, 2H), 3.72 (s, 3H), 2.25 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.44, 172.35, 165.38, 164.28,
,
δ
137.45, 136.17, 135.95, 133.82, 130.33, 129.47, 128.62, 126.70, 126.16, 126.03, 112.43, 75.78, 52.41, 30.67,
17.89 ppm. HRMS (EI) calc. for C21H17N3O4S+ 407.0940; found 407.0941.
Methyl (Z)-2-cyano-2-(3-(4-((4-fluorophenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate (30). White
solid, Yield: 43%. Mp 231.7–232.5 ◦C; 1H-NMR (DMSO-d6):
δ
10.46 (s, 1H), 8.10 (d, J = 8.4 Hz, 2H),
7.82 (dd, J = 8.8, 5.0 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.22 (t, J = 8.8 Hz, 2H), 4.10 (s, 2H), 3.72 (s,
3H) ppm. 13C-NMR (DMSO-d6): 173.40, 172.34, 165.36, 164.38, 158.39 (d, 1JCF = 239.1 Hz), 137.51,
δ
136.17, 135.28 (d, 4JCF = 2.5 Hz), 129.47, 128.65, 122.33 (d, 3JCF = 7.8 Hz), 115.21 (d, 2JCF = 22.1 Hz),
112.40, 75.79, 52.40, 32.24 ppm. 19F-NMR (DMSO-d6): δ −118.51 –
−
118.61 (m, 1F) ppm. HRMS (EI)
calc. for C20H14FN3O4S+ 411.0689; found 411.0690.
Methyl (Z)-2-cyano-2-(3-(4-((3-cyano-4-fluorophenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate
◦
1
(
31). White solid, Yield: 40%. Mp 264.2–265.1 C; H-NMR (DMSO-d6):
J = 5.8, 2.6 Hz, 1H), 8.11 (d, J = 8.4 Hz, 3H), 7.63 (d, J = 8.4 Hz, 2H), 7.57 (t, J = 9.2 Hz, 1H), 4.10 (s, 2H),
3.73 (s, 3H) ppm. 13C-NMR (DMSO-d6): 173.39, 172.30, 165.34, 164.80, 158.49 (d, 1JCF = 251.2 Hz),
137.85, 136.05 (d, 3JCF = 6.5 Hz), 135.57, 129.61, 128.76, 127.79 (d, 3JCF = 8.1 Hz), 124.38, 116.99 (d, 2JCF
δ 10.75 (s, 1H), 8.31 (dd,
δ

Molecules 2019, 24, 2780
20 of 24
= 20.4 Hz), 113.95, 112.42, 99.85 (d, 2JCF = 16.1 Hz), 75.79, 52.41, 32.25 ppm. 19F-NMR (DMSO-d6):
−114.31–−114.38 (m, 1F) ppm. HRMS (EI) calc. for C21H13FN4O4S+ 436.0642; found 436.0640.
δ
Methyl (Z)-2-(3-(4-((4-chlorophenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (32). White
solid, Yield: 44%. Mp 280.1–280.9 ◦C; 1H-NMR (DMSO-d6):
10.53 (s, 1H), 8.10 (d, J = 8.4 Hz, 2H),
7.85 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 4.10 (s, 2H), 3.72 (s, 3H) ppm.
δ
13C-NMR (DMSO-d6):
δ 173.40, 172.33, 165.36, 164.57, 137.92, 137.60, 136.07, 129.50, 128.72, 128.55,
127.49, 121.96, 112.40, 75.79, 52.41, 32.24 ppm. HRMS (EI) calc. for C20H1435ClN3O4S+ 427.0394; found
427.0393; calc. for C20H1437ClN3O4S+ 429.0364; found 429.0369.
Methyl (Z)-2-(3-(4-((4-bromophenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (33). White
solid, Yield: 42%. Mp 306.2–307.1 ◦C; 1H-NMR (DMSO-d6):
δ
10.53 (s, 1H), 8.10 (d, J = 8.4 Hz, 2H),
7.80 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 4.10 (s, 2H), 3.73 (s, 3H) ppm.
13C-NMR (DMSO-d6):
δ 173.39, 172.32, 165.36, 164.58, 138.35, 137.61, 136.07, 131.46, 129.50, 128.73,
122.32, 115.58, 112.40, 75.80, 52.41, 32.25 ppm. HRMS (EI) calc. for C20H1479BrN3O4S+ 470.9888; found
470.9887; calc. for C20H1481BrN3O4S + 472.9868; found 472.9863.
Methyl (Z)-2-cyano-2-(3-(4-((4-iodophenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate (34). White
solid, Yield: 45%. Mp 315.8–316.6 ◦C; 1H-NMR (DMSO-d6):
δ
10.49 (s, 1H), 8.09 (d, J = 8.8 Hz, 2H),
7.72 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 4.10 (s, 2H), 3.72 (s, 3H) ppm.
13C-NMR (DMSO-d6):
δ 173.39, 172.32, 165.36, 164.56, 138.82, 137.59, 137.30, 136.09, 129.49, 128.72,
122.56, 112.40, 87.64, 75.79, 52.42, 32.25 ppm. HRMS (EI) calc. for C20H14IN3O4S+ 518.9750; found
518.9751.
Methyl (Z)-2-cyano-2-(4-oxo-3-(4-((4-(trifluoromethyl)phenyl)carbamoyl)phenyl)thiazolidin-2-ylidene)
acetate (35). White solid, Yield: 40%. Mp 264.2–265.1 ◦C; 1H-NMR (DMSO-d6):
δ
10.75 (s, 1H), 8.13 (d,
J = 8.0 Hz, 2H), 8.05 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.0 Hz, 2H), 4.11 (s, 2H), 3.73
(s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.40, 172.33, 165.36, 165.00, 142.61, 137.78, 135.87, 129.55, 128.85,
125.93 (q, 3JCF = 3.6 Hz), 124.35 (q, 1JCF = 269.5 Hz), 123.80 (q, 2JCF = 31.8 Hz), 120.23, 112.42, 75.78,
52.40, 32.25 ppm. 19F-NMR (DMSO-d6): δ −60.35 (s, 3F) ppm. HRMS (EI) calc. for C21H14F3N3O4S+
461.0657; found 461.0658.
Methyl (Z)-2-cyano-2-(3-(4-((4-methoxyphenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate (36).
White solid, Yield: 55%. Mp 268.9–269.7 ◦C; 1H-NMR (DMSO-d6):
δ
10.29 (s, 1H), 8.10 (d, J = 7.2 Hz
,
2H), 7.71 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 7.2 Hz, 2H), 6.95 (d, J = 8.0 Hz, 2H), 4.10 (s, 2H), 3.76 (s, 3H),
3.73 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.37, 172.31, 165.36, 163.96, 155.69, 137.32, 136.40, 131.97,
129.39, 128.53, 122.10, 113.76, 112.35, 75.83, 55.17, 52.38, 32.21 ppm. HRMS (EI) calc. for C21H17N3O5S+
423.0889; found 423.0891.
Methyl (Z)-2-(3-(4-((4-(tert-butyl)phenyl)carbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (37).
White solid, Yield: 51%. Mp 256.1–257.0 ◦C; 1H-NMR (DMSO-d6):
δ
10.34 (s, 1H), 8.10 (d, J = 8.4 Hz,
2H), 7.71 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.8 Hz, 2H), 4.10 (s, 2H), 3.72 (s, 3H),
1.29 (s, 9H) ppm. 13C-NMR (DMSO-d6):
δ 173.42, 172.38, 165.37, 164.21, 146.19, 137.40, 136.35, 129.42,
128.63, 125.24, 120.23, 112.39, 75.74, 52.41, 34.06, 32.25, 31.18 ppm. HRMS (EI) calc. for C24H23N3O4S+
449.1409; found 449.1410.
Methyl (Z)-2-cyano-2-(3-(4-(naphthalen-2-ylcarbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)acetate (38). White
solid, Yield: 48%. Mp 285.0–286.0 ◦C; 1H-NMR (DMSO-d6):
δ
10.61 (s, 1H), 8.49 (d, J = 1.2 Hz, 1H), 8.16
(d, J = 8.4 Hz, 2H), 7.95–7.84 (m, 4H), 7.63 (t, J = 8.4 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.4 Hz,
1H), 4.11 (s, 2H), 3.73 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.41, 172.35, 165.38, 164.66, 137.55, 136.57,
δ
136.27, 133.27, 130.07, 129.50, 128.73, 128.18, 127.44, 126.40, 124.88, 120.96, 116.78, 112.41, 75.81, 52.41,
32.25 ppm. HRMS (EI) calc. for C24H17N3O4S+ 443.0940; found 443.0938.
Methyl (Z)-2-(3-(4-(benzylcarbamoyl)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate (39). White solid,
Yield: 68%. Mp 117.3–118.1 ◦C; 1H-NMR (DMSO-d6):
δ 9.22 (t, J = 5.6 Hz, 1H), 8.03 (d, J = 8.4 Hz,

Molecules 2019, 24, 2780
21 of 24
2H), 7.54 (d, J = 8.4 Hz, 2H), 7.37–7.32 (m, 4H), 7.27–7.22 (m, 1H), 4.51 (d, J = 5.6 Hz, 2H), 4.08 (s, 2H),
3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 173.39, 172.35, 165.37, 165.20, 139.46, 137.20, 135.82, 129.39,
128.28, 128.23, 127.27, 126.78, 112.33, 75.78, 52.39, 42.72, 32.22 ppm. HRMS (EI) calc. for C21H17N3O4S+
407.0940; found 407.0939.
Methyl (Z)-2-(3-(4-((5-acetylnaphthalen-2-yl)carbam◦oyl)phenyl)-4-oxothiazolidin-2-ylidene)-2-cyanoacetate
1
(
45). White solid, Yield: 43%. Mp 275.0–275.8 C; H-NMR (DMSO-d6):
δ
10.73 (s, 1H), 9.10 (d,
J = 1.6 Hz, 1H), 8.17 (d, J = 8.4 Hz, 2H), 8.12 (d, J = 7.2 Hz, 1H), 8.11–8.08 (m, 2H), 8.01 (d, J = 8.8 Hz,
1H), 7.62 (d, J = 8.4 Hz, 2H), 7.53 (t, J = 7.8 Hz, 1H), 4.11 (s, 2H), 3.73 (s, 3H), 2.74 (s, 3H) ppm. 13C-NMR
(DMSO-d6):
δ 201.53, 173.40, 172.34, 165.37, 164.72, 138.60, 137.59, 136.18, 134.45, 132.43, 130.57, 129.84,
129.60, 129.45, 128.85, 128.81, 123.62, 121.26, 115.06, 112.38, 75.82, 52.40, 32.25, 30.08 ppm. HRMS (EI)
calc. for C26H19N3O5S+ 485.1045; found 485.1046.
3.2.4. Synthesis of Compounds 42, 43 and 46
Synthesis of (Z)-2-((4-(2-(1-cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-
yl)benzamido)methyl)-benzoic acid (42)
TCDI (2.4 mmol) was added to a solution of compound IM in THF (10 mL). Then the mixture was
stirred at room temperature for 3 h. Then the mixture was added compound 42b (2 mmol) and stirred
at 50 ◦C for 2 h. The solvent was removed under reduced pressure after cooling to room temperature
and the residue was purified by column chromatography (DCM/MeOH=20:3, V/V) to give 42 in a yield
of 38%. White solid, Yield: 38%. Mp 217.3–218.1 ◦C; 1H-NMR (DMSO-d6):
5.6 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 7.6 Hz, 1H), 7.58–7.52 (m, 3H), 7.43 (d, J = 7.6 Hz, 1H),
7.37 (t, J = 7.6 Hz, 1H), 4.85 (d, J = 5.6 Hz, 2H), 4.09 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ 13.08 (s, 1H), 9.14 (t, J =
δ
173.93, 172.89, 168.93, 165.92, 165.87, 140.81, 137.76, 136.24, 132.51, 130.87, 129.94, 128.74, 127.76, 127.22,
112.86, 76.22, 52.90, 41.80, 32.73 ppm. HRMS (EI) calc. for C22H17N3O6S+ 451.0844; found 451.0838.
Synthesis of (Z)-3-((4-(2-(1-cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-
yl)benzamido)methyl) benzoic acid (43)
CF3COOH (1.5 mL) was added to a solution of compound 43c (1 mmol) in DCM (15 mL). Then
the mixture was stirred at room temperature overnight. The solvent was removed under reduced
pressure and the residue was crystallized from DCM/MeOH to give compound 43 in a yield of 85%.
White solid, Mp 205.7–206.6 ◦C; 1H-NMR (DMSO-d6):
δ 12.92 (s, 1H), 9.26 (t, J = 5.6 Hz, 1H), 8.02
(d, J = 8.4 Hz, 2H), 7.94 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 8.4 Hz, 2H),
7.47 (t, J = 8.0 Hz, 1H), 4.56 (d, J = 5.6 Hz, 2H), 4.09 (s, 2H), 3.71 (s, 3H) ppm. 13C-NMR (DMSO-d6):
δ
173.34, 172.29, 167.22, 165.34, 165.25, 139.96, 137.26, 135.68, 131.88, 130.84, 129.42, 128.57, 128.24,
128.21, 127.81, 112.30, 75.81, 52.37, 42.53, 32.19 ppm. HRMS (ESI) calc. for C22H17N3O6SNa+ (M +
Na)+, 474.0736; found 474.0737.
Synthesis of 2-(((E)-(4-((Z)-2-(1-cyano-2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)benzamido)-
methylene)amino)benzoic acid (46)
A drop of concentrated HCl was added to a solution of compound 46b (1 mmol) and
2-formylbenzoic acid in EtOH (30 mL). Then the mixture was stirred at room temperature until
the reaction was completed. The solvent was removed under reduced pressure and the residue was
crystallized from DCM/MeOH to give compound 46 in yield of 80%. White solid, Yield: 80%. Mp
222.8–223.5 ◦C; 1H-NMR (DMSO-d6):
(d, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.55 (t, J = 7.6 Hz, 1H), 4.10 (s, 2H),
3.72 (s, 3H) ppm. 13C-NMR (DMSO-d6):
173.39, 172.33, 168.04, 165.36, 162.28, 147.08, 137.63, 134.78,
δ 13.26 (s, 1H), 12.25 (s, 1H), 9.24 (s, 1H), 8.12 – 8.05 (m, 3H), 7.92
δ
134.53, 132.00, 130.67, 130.30, 129.69, 129.51, 128.72, 126.68, 112.35, 75.80, 52.40, 32.24 ppm. HRMS (ESI)
calc. for C22H16N4O6SNa+ (M + Na)+, 487.0688; found 487.0689.

Molecules 2019, 24, 2780
22 of 24
3.3. In Vitro Assays
The plasmid pET-19b–hDHODH (Met30-Arg396) was transformed into BL21 (DE3) E. coli cells
for protein production. Cells were grown at 37 ◦C in a rich medium, and were induced with 1 mM
isopropyl-β-D-thiogalactoside (IPTG) at an OD600 of 0.6–0.8. After incubation for an additional 18 h
at 16 ◦C, the cells were harvested by centrifugation. The harvested cells were suspended in buffer
A (50 mM HEPES pH 8.0, 400 mM NaCl, 10% glycerol) and disrupted by a high-pressure cracker at
4 ◦C. Triton X-100 was added to a final concentration of 1% into the lysate before centrifugation. The
supernatant was loaded onto a HiTrap Chelating column (5 mL; GE Healthcare, Uppsala, Sweden).
Pure hDHODH was eluted with buffer A, 0.1% Triton X-100 and 160 mM imidazole.
The purified hDHODH was diluted into a final concentration of 10 nM with the assay buffer
contained 50 mM HEPES pH 8.0, 150 mM KCl, 0.1% Triton X-100. UQ0 and DCIP were added to the
assay buffer to final concentrations of 100 and 120
a final concentration of 500 M to initiate the reaction. Brequinar was measured as the positive control.
Inhibition rate was calculated from (1-Vi/V0) 100. For the determination of the IC50 values, eight to
µM, respectively. The dihydroorotate was added to
µ
×
nine different concentrations were applied. Each inhibitor concentration point was tested in triplicate.
IC50 values were calculated using the sigmoidal fitting option of the program Origin 8.0.
4. Conclusions
In conclusion, based on our previous work, three series of 4-thiazolidinone derivatives including
biphenyl, diphenyl ether and amide groups were designed and synthesized as hDHODH inhibitors.
The preliminary structure–activity relationships were investigated. The hDHODH inhibitory activities
of several newly synthesized compounds and compounds
compounds and 37 with IC50 values of 1.32 and 1.45 M, respectively. Further modifications will be
investigated to improve the activity of 4-thiazolidinone derivatives.
7 and 8 are at the same level, especially
9
µ
Supplementary Materials: Spectrums for target compounds 7–46 could be accessed in supplementary materials.
Author Contributions: Conceptualization, X.X., L.Z. (Lili Zhu) and F.Z.; investigation, F.Z. and L.Q.; methodology,
F.Z., L.Q., X.X., G.Y., T.Q., L.Z. (Letian Zhang) and S.L.; software, L.Q., F.Z., T.Q., S.L. and H.L.; data curation, X.X.,
F.Z., L.Q., G.Y. and L.Z. (Lili Zhu); writing—original draft preparation, F.Z. and G.Y.; writing—review and editing,
X.X. and L.Z (Lili Zhu).; supervision, X.X. and L.Z. (Lili Zhu).
Funding: X.X. and H.L. innovation Program of Shanghai Municipal Education Commission (201701070002E00037).
The Fundamental Research Funds for the Central Universities.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Surekha, K.; Prabhu, D.; Richard, M.; Nachiappan, M.; Biswal, J.; Jeyakanthan, J. Investigation of
vital pathogenic target orotate phosphoribosyltransferases (OPRTase) from Thermus thermophilus HB8:
Phylogenetic and molecular modeling approach. Gene 2016, 583, 102–111. [CrossRef] [PubMed]
Roon, D.E.N.V.; Jansen, T.L.T.A.; Houtman, N.M.; Spoelstra, P.; Brouwers, J.R.B.J. Leflunomide for the
Treatment of Rheumatoid Arthritis in Clinical Practice. Am. J. Med. Sci. 2002, 323, 190–193.
Liu, S.; Neidhardt, E.A.; Grossman, T.H.; Ocain, T.; Clardy, J. Structures of human dihydroorotate
dehydrogenase in complex with antiproliferative agents. Structure 2000, 8, 25–33. [CrossRef]
Jöckel, J.; Wendt, B.; Löffler, M. Structural and functional comparison of agents interfering with dihydroorotate,
succinate and NADH oxidation of rat liver mitochondria. Biochem. Pharmacol. 1998, 56, 1053–1060. [CrossRef]
Breedveld, F.C.; Dayer, J.M. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann.
Rheum. Dis. 2000, 59, 841–849. [CrossRef] [PubMed]
2.
3.
4.
5.
6.
7.
Löffler, M.; Fairbanks, L.D.; Zameitat, E.; Marinaki, A.M.; Simmonds, H.A. Pyrimidine pathways in health
and disease. Trends Mol. Med. 2005, 11, 430–437. [CrossRef] [PubMed]
Rusai, K.; Schmaderer, C.; Baumann, M.; Chmielewski, S.; Prókai, Á.; Kis, E.; Szabó, A.J.; Leban, J.; Doblhofer, R.;
Ammendola, A. Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a
rat model of renal transplantation. Transplantation 2012, 93, 1101–1107. [CrossRef] [PubMed]

Molecules 2019, 24, 2780
23 of 24
8.
9.
Vyas, V.K.; Ghate, M. Recent developments in the medicinal chemistry and therapeutic potential of
dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev. Med. Chem. 2011, 11, 1039–1055. [CrossRef]
Sykes, D.B.; Kfoury, Y.S.; Mercier, F.E.; Wawer, M.J.; Law, J.M.; Haynes, M.K.; Lewis, T.A.; Schajnovitz, A.;
Jain, E.; Lee, D. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute
Myeloid Leukemia. Cell 2016, 167, 171–186. [CrossRef]
10. Dexter, D.L.; Hesson, D.P.; Ardecky, R.J.; Rao, G.V.; Tippett, D.L.; Dusak, B.A.; Paull, K.D.;
Plowman, J.; DeLarco, B.M.; Narayanan, V. Activity of a novel 4-quinolinecarboxylic acid, NSC
368390 [6-fluoro-2-(20-fluoro-1, 10-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt], against
experimental tumors. Cancer Res. 1985, 45, 5563–5568.
11. Cramer, D.V.; Chapman, F.A.; Jaffee, B.D.; Jones, E.A.; Knoop, M.; Hreha-Eiras, G.; Makowka, L. The effect of
a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.
Transplantation 1992, 53, 303–307. [CrossRef] [PubMed]
12. Scott, D.L.; Wolfe, F.; Huizinga, T.W.J. Rheumatoid arthritis. Lancet 2010, 376, 1094–1108. [CrossRef]
13. Dang, W.; Wang, W.; Chen, W.; Lian, F.; Li, L.; Ying, H.; Xu, Y.; Zhang, N.; Chen, Y.; Liu, M. Pharmacologic
inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia
cells. Haematologica 2018, 103, 1472–1483.
14. Sainas, S.; Pippione, A.C.; Lupino, E.; Giorgis, M.; Circosta, P.; Gaidano, V.; Goyal, P.; Bonanni, D.;
Rolando, B.; Cignetti, A. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo [1,5-a]pyridine
Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. J. Med. Chem. 2018, 61, 6034–6055.
[CrossRef] [PubMed]
15. Munierlehmann, H.; Vidalain, P.O.; Tangy, F.; Janin, Y.L. On Dihydroorotate Dehydrogenases and Their
Inhibitors and Uses. J. Med. Chem. 2013, 56, 3148–3167. [CrossRef] [PubMed]
16. Finckh, A.; Dehler, S.; Gabay, C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor
inhibitors in rheumatoid arthritis: A population-based study. Ann. Rheum. Dis. 2009, 68, 33. [CrossRef]
[PubMed]
17. Rückemann, K.; Fairbanks, L.D.; Carrey, E.A.; Hawrylowicz, C.M.; Richards, D.F.; Kirschbaum, B.;
Simmonds, H.A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes
from healthy humans. J. Biol. Chem. 1998, 273, 21682–21691. [CrossRef] [PubMed]
18. Christian, C.; Li, D.K.; Freedman, M.S.; Philippe, T.; Hadj, B.; Dazhe, W.; Amit, B.O.; Traboulsee, A.L.;
Reiman, L.E.; O’Connor, P.W. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing
multiple sclerosis: Safety and efficacy results up to 8.5 years. Mult. Scler. 2012, 18, 1278–1289.
19. Confavreux, C.; O’Connor, P.; Comi, G.; Freedman, M.S.; Miller, A.E.; Olsson, T.P.; Wolinsky, J.S.; Bagulho, T.;
Delhay, J.L.; Dukovic, D. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER):
A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13, 247–256. [CrossRef]
20. Claussen, M.C.; Korn, T. Immune mechanisms of new therapeutic strategies in MS: Teriflunomide.
Clin. Immunol. 2012, 142, 49–56. [CrossRef]
21. Maroun, J.; Ruckdeschel, J.; Natale, R.; Morgan, R.; Dallaire, B.; Sisk, R.; Gyves, J. Multicenter phase II study
of brequinar sodium in patients with advanced lung cancer. Cancer Chemother. Pharmacol. 1993, 32, 64–66.
[CrossRef] [PubMed]
22. Dodion, P.F.; Wagener, T.; Stoter, G.; Drozd, A.; Lev, L.M.; Skovsgaard, T.; Renard, J.; Cavalli, F. Phase II trial
with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: A study of the Early
Clinical Trials Group of the EORTC. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 1990, 1, 79. [CrossRef]
23. Cramer, D.V.; Chapman, F.A.; Makowka, L. The use of brequinar sodium for transplantation. Ann. N. Y.
Acad. Sci. 2010, 696, 216–226. [CrossRef] [PubMed]
24. Min, Q.; Gang, Z.; Wang, Q.Y.; Hao, Y.X.; Dong, H.; Yuan, Z.; Shi, P.Y. Characterization of Dengue Virus
Resistance to Brequinar in Cell Culture. Antimicrob. Agents Chemother. 2010, 54, 3686–3695.
25. Schnellrath, L.C.; Damaso, C.R. Potent antiviral activity of brequinar against the emerging Cantagalo virus
in cell culture. Int. J. Antimicrob. Agents 2011, 38, 435–441. [CrossRef] [PubMed]
26. Herrlinger, K.R.; Diculescu, M.; Fellermann, K.; Hartmann, H.; Howaldt, S.; Nikolov, R.; Petrov, A.; Reindl, W.;
Otte, J.M.; Stoynov, S. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel
disease: The ENTRANCE study. Gastroenterology 2013, 7, 636–643.
27. Fitzpatrick, L.R.; Ammendola, A. Vidofludimus Improves Colitis in Rats by a Dual Mode of Action.
J. Pharmacol. Exp. Ther. 2012, 342, 850–860. [CrossRef] [PubMed]

Molecules 2019, 24, 2780
24 of 24
28. Fitzpatrick, L.R.; Small, J.S.; Doblhofer, R.; Henning, S.W.; Ammendola, A. P012 Vidofludimus inhibits IL-17
and improves hapten-induced colitis in young rats by a unique dual mode of action. J. Pharmacol. Exp. Ther.
2012, 142, 850–860. [CrossRef]
29. Lewis, T.A.; Sykes, D.B.; Law, J.M.; Muñoz, B.; Rustiguel, J.K.; Nonato, M.C.; Scadden, D.T.; Schreiber, S.L.
Development of mL390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid
Leukemia. ACS Med. Chem. Lett. 2016, 7, 1112. [CrossRef]
30. Mjgw, L.; Imm, V.L.; Drummond, C.J.; Chu, S.; Healy, A.R.; Popova, G.; Pastor, F.A.; Mollick, T.; Darekar, S.;
Sedimbi, S.K. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation
blockage. Nat. Commun. 2018, 9, 1107.
31. Zeng, F.; Qi, T.; Li, C.; Li, T.; Li, H.; Li, S.L.; Zhu, L.; Xu, X. Synthesis, structure-activity relationship
and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate
dehydrogenase. Medchemcomm 2017, 8, 1297–1302. [CrossRef] [PubMed]
32. Song, W.; Li, S.; Tong, Y.; Wang, J.; Quan, L.; Chen, Z.; Zhao, Z.; Xu, Y.; Zhu, L.; Qian, X. Structure-based
design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents. Medchemcomm 2016
,
7, 1441–1448. [CrossRef]
Sample Availability: Samples of the compounds 7–46 are available from the authors.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).